WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...

Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...

UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...

WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift ® System, a proven, minimally ...

Urolift is a minimally invasive procedure to help treat an enlarged prostate, known as benign prostatic hyperplasia (BPH). Medicare will typically cover Urolift procedures when a doctor deems them ...

MINNEAPOLIS--(BUSINESS WIRE)--In 2012, Dr. Jafar Golzarian performed the first prostate artery embolization (PAE) in the U.S. Today, he is confidently performing PAE on an outpatient basis at North ...

Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.